Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Evaluate the Efficacy of Bifidobacterium BB-12® in the Treatment of Infantile Colic

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients are included in the study if they meet all the following criteria:~* Exclusively breastfed healthy infants of both sexes, aged ≤ 7 weeks.~* Diagnosis of IC according to Rome III criteria.~* Written informed consent of the parent/tutor.~Exclusion Criteria:~Patients are excluded from this study if they meet any of the following criteria:~* Birth weight \< 2500 g.~* Gestational age \< 37 weeks.~* APGAR 5 minutes \< 7.~* Formula feeding.~* Stunting/loss of weight (\< 100 g/weeks from birth to the last reported weight).~* Neurological diseases.~* Known or suspected food allergy.~* Gastroesophageal reflux disease.~* Use of substances that alter gut microbiota (probiotics, prebiotics, antibiotics, gastric acidity inhibitors) in the last 2 weeks prior the enrollment.~* History of fever and/or infectious diseases in the last 2 weeks prior to enrollment.~* Ongoing systemic infections.~* History of congenital infections.~* Chronic intestinal diseases (cystic fibrosis or other forms of primitive pancreatic insufficiency)~* Primitive or secondary malformations of the gastrointestinal tract (such as esophageal atresia, intestinal atresia, short bowel syndrome, malrotation).~* Metabolic diseases.~* Genetic diseases and chromosomal abnormalities.~* Primary or secondary immunodeficiencies.~* Not sufficient reliability or presence of conditions that may result in non-compliance/adherence of the patient to the Protocol.~* Previous participation in this study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 7 Weeks
- Healthy Volunteers: f

Study Arms:
- Group I (Type: EXPERIMENTAL): patients who take Bifidobacterium BB-12® (Bifidolactis Infant), 6 drops a day (guaranteeing a billion of living cells) for 28 consecutive days;
- Group II (Type: PLACEBO_COMPARATOR): patients who take Bifidolactis Infant Placebo 6 drops a day for 28 consecutive days.

Based on this trial design, predict the completion outcome and termination type (if applicable).